Skip to main content

Biopharmaceutical firm GP Pharm, which specializes in injectable products in the fields of oncology and urology, has signed a licensing agreement with Zeltia to distribute the drug Lutrate® (Leuprorelina). This drug has been developed by GP Pharm and is used to treat prostate cancer.

The contract between GP Pharm and Zeltia lays out that PharmaMar, a subsidiary of Zeltia, has the exclusive rights to distribute Lutrate® in Italy and will pay royalties to GP Pharm. GP Pharm will continue to manufacture the drug, so there will be no additional investment on behalf of PharmaMar, which will use their existing infrastructure in Italy to market this drug.

More information is available in the press release.

 

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.